Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2022-02-02 Purchase | 2022-02-04 08:28 am | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 201,602 | $7.7966 | $1,571,810 | 5,429,111 (Indirect Direct) | View |
2022-02-02 Purchase | 2022-02-03 09:21 am | Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar Director | 10,000 | $8.01 | $80,100 | 29,226 (Direct) | View |
2022-02-02 Purchase | 2022-02-03 07:04 am | Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director | 3,000 | $7.78 | $23,340 | 3,000 (Direct) | View |
2021-11-23 Purchase | 2021-12-08 4:05 pm | Taysha Gene Therapies Inc. | TSHA | Session R.A. II CEO 10% Owner | 42,518 | $12.44 | $529,102 | 9,473,100 (Indirect Direct) | View |
2021-11-24 Purchase | 2021-11-29 5:01 pm | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 2,202 | $13.19 | $29,044 | 5,249,509 (Indirect Direct) | View |
2021-11-23 Purchase | 2021-11-24 07:58 am | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 20,000 | $12.54 | $250,800 | 5,247,307 (Indirect Direct) | View |
2021-08-18 Sale | 2021-08-20 5:52 pm | Taysha Gene Therapies Inc. | TSHA | Alam Kamran CFO | 33,000 | $16.88 | $557,023 | 298,121 (Direct) | View |
2021-06-29 Sale | 2021-07-01 6:32 pm | Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R & D | 79,000 | $22.63 | $1,787,936 | 593,589 (Direct) | View |
2021-05-20 Purchase | 2021-05-24 08:39 am | Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Director | 1,170 | $22.35 | $26,150 | 1,092,271 (Indirect Direct) | View |
2021-05-14 Purchase | 2021-05-17 07:48 am | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 12,000 | $20.98 | $251,760 | 5,227,307 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2022-04-06 Option Award | 2022-04-08 4:27 pm | N/A 2032-04-06 | Taysha Gene Therapies Inc. | TSHA | Alam Kamran CFO | 40,000 | $0 | 40,000 (Direct) | View |
2022-04-06 Option Award | 2022-04-08 4:26 pm | N/A 2032-04-06 | Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R & D | 40,325 | $0 | 40,325 (Direct) | View |
2022-02-23 Option Award | 2022-02-25 4:20 pm | N/A 2032-02-23 | Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R & D | 80,650 | $0 | 80,650 (Direct) | View |
2022-02-23 Option Award | 2022-02-25 4:18 pm | N/A 2032-02-23 | Taysha Gene Therapies Inc. | TSHA | Alam Kamran CFO | 80,000 | $0 | 80,000 (Direct) | View |
2022-02-23 Option Award | 2022-02-25 4:17 pm | N/A 2032-02-23 | Taysha Gene Therapies Inc. | TSHA | Session R.A. II CEO 10% Owner | 217,850 | $0 | 217,850 (Direct) | View |
2021-06-17 Option Award | 2021-06-21 5:05 pm | N/A 2031-06-17 | Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director | 15,500 | $0 | 15,500 (Direct) | View |
2021-06-17 Option Award | 2021-06-21 5:04 pm | N/A 2031-06-17 | Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar Director | 15,500 | $0 | 15,500 (Direct) | View |
2021-06-17 Option Award | 2021-06-21 5:02 pm | N/A 2031-06-17 | Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Director | 15,500 | $0 | 15,500 (Direct) | View |
2021-06-17 Option Award | 2021-06-21 5:01 pm | N/A 2031-06-17 | Taysha Gene Therapies Inc. | TSHA | Reape Kathleen Director | 15,500 | $0 | 15,500 (Direct) | View |
2021-06-17 Option Award | 2021-06-21 5:01 pm | N/A 2031-06-17 | Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director | 15,500 | $0 | 15,500 (Direct) | View |
2021-06-17 Option Award | 2021-06-21 4:59 pm | N/A 2031-06-17 | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 15,500 | $0 | 15,500 (Direct) | View |
2020-12-31 Ownership | 2021-02-16 5:45 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 0 | $0 | 5,215,307 (Indirect) | View |
2020-12-31 Ownership | 2021-02-16 5:45 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 80,000 | $0 | 5,215,307 (Indirect) | View |
2021-01-19 Option Award | 2021-01-20 8:22 pm | N/A 2031-01-19 | Taysha Gene Therapies Inc. | TSHA | Session R.A. II CEO 10% Owner | 199,700 | $0 | 199,700 (Direct) | View |
2021-01-19 Option Award | 2021-01-20 8:21 pm | N/A 2031-01-19 | Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R & D | 80,000 | $0 | 80,000 (Direct) | View |
2021-01-19 Option Award | 2021-01-20 8:20 pm | N/A 2031-01-19 | Taysha Gene Therapies Inc. | TSHA | Alam Kamran CFO | 70,000 | $0 | 70,000 (Direct) | View |
2020-11-23 Option Award | 2020-11-24 4:42 pm | N/A 2030-11-23 | Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director | 31,000 | $0 | 31,000 (Direct) | View |
2020-11-23 Option Award | 2020-11-24 4:41 pm | N/A 2030-11-23 | Taysha Gene Therapies Inc. | TSHA | Reape Kathleen Director | 31,000 | $0 | 31,000 (Direct) | View |
2020-09-28 Conversion | 2020-09-30 4:39 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R & D | 7,373 | $0 | 672,589 (Direct) | View |
2020-09-28 Conversion | 2020-09-30 4:38 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Director | 2,092,571 | $0 | 1,091,101 (Indirect) | View |
2020-09-28 Conversion | 2020-09-30 4:37 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar Director | 36,873 | $0 | 19,226 (Direct) | View |
2020-09-28 Conversion | 2020-09-30 4:37 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 10,155,618 | $0 | 2,020,102 (Indirect) | View |
2020-09-23 Option Award | 2020-09-25 5:14 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | PRASAD SUYASH CMO and Head of R & D | 668,745 | $0 | 668,745 (Direct) | View |
2020-09-23 Option Award | 2020-09-25 5:13 pm | N/A 2030-09-23 | Taysha Gene Therapies Inc. | TSHA | Nolan Sean P. Director | 31,000 | $0 | 31,000 (Direct) | View |
2020-09-23 Option Award | 2020-09-25 5:12 pm | N/A 2030-09-23 | Taysha Gene Therapies Inc. | TSHA | Nagendran Sukumar Director | 31,000 | $0 | 31,000 (Direct) | View |
2020-09-23 Option Award | 2020-09-25 5:11 pm | N/A 2030-09-23 | Taysha Gene Therapies Inc. | TSHA | Manning Paul B Director 10% Owner | 31,000 | $0 | 31,000 (Direct) | View |
2020-09-23 Option Award | 2020-09-25 5:09 pm | N/A 2030-09-23 | Taysha Gene Therapies Inc. | TSHA | Donenberg Phillip B. Director | 31,000 | $0 | 31,000 (Direct) | View |
2020-09-23 Option Award | 2020-09-25 5:08 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Alam Kamran CFO | 331,121 | $0 | 331,121 (Direct) | View |
2020-09-23 Ownership | 2020-09-23 8:32 pm | N/A N/A | Taysha Gene Therapies Inc. | TSHA | Session R.A. II CEO 10% Owner | 0 | $0 | 9,430,582 (Direct) | View |